Journal
EUROPEAN JOURNAL OF CANCER
Volume 135, Issue -, Pages 62-65Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2020.05.026
Keywords
COVID-19; SARS-CoV-2; Cytokine storm; AntiePD-1; AntieIL-6R; Pembrolizumab; Tocilizumab
Categories
Ask authors/readers for more resources
While confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease's damage. Although no proven effective therapies for treating patients with COVID-19 or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome coronavirus 2 and its interplay with hosts provides a significant number of potential drug targets and the potential to repurpose drugs already tested in other diseases. Herein, we report the biological rationale of immune-activating drugs and a brief summary of literature data on the potential therapeutic value of immune checkpoint inhibitors that have been recently tested beyond cancer treatment for their potential to restore cellular immunocompetence. (C) 2020 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available